[go: up one dir, main page]

HRP20130549T4 - Spojevi i njihove soli specifični za ppar receptore i egf receptore te njihova primjena u području medicine - Google Patents

Spojevi i njihove soli specifični za ppar receptore i egf receptore te njihova primjena u području medicine Download PDF

Info

Publication number
HRP20130549T4
HRP20130549T4 HRP20130549TT HRP20130549T HRP20130549T4 HR P20130549 T4 HRP20130549 T4 HR P20130549T4 HR P20130549T T HRP20130549T T HR P20130549TT HR P20130549 T HRP20130549 T HR P20130549T HR P20130549 T4 HRP20130549 T4 HR P20130549T4
Authority
HR
Croatia
Prior art keywords
compound
aminophenyl
propionic acid
ethoxy
use according
Prior art date
Application number
HRP20130549TT
Other languages
English (en)
Inventor
Giancarlo Naccari
Sergio Baroni
Original Assignee
Nogra Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37579831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130549(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nogra Pharma Limited filed Critical Nogra Pharma Limited
Publication of HRP20130549T1 publication Critical patent/HRP20130549T1/hr
Publication of HRP20130549T4 publication Critical patent/HRP20130549T4/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Claims (11)

1. Spoj i njegove soli, izabran iz grupe koja obuhvaća: [image] [image] i [image]
2. Spoj prema zahtjevu 1 u enantiomerski čistom R ili S obliku.
3. Spoj izabran iz grupe koja obuhvaća: (+-)-2-hidroksi-3-(3’-aminofenil) propionska kiselina (spoj 20) (+-)-2-metoksi-2-(4’-aminofenil) octena kiselina (spoj 23) (+-)-2-etoksi-2-(3’-aminofenil) octena kiselina (spoj 32) (+-)-2-etoksi-2-(4’-aminofenil) octena kiselina (spoj 33) (+-)-2-metoksi-3-(4’-aminofenil) propionska kiselina (spoj 34) (+-)-2-etoksi-3-(4’-aminofenil) propionska kiselina (spoj 39) i (+-)-2-etoksi-3-(3’-aminofenil) propionska kiselina (spoj 40) za uporabu u medicini.
4. Spoj 2-metoksi-3-(3’-aminofenil)propionska kiselina ili (±)-2-hidroksi-3-(4’-aminofenil)propionska kiselina (spoj 21) za uporabu u medicini.
5. Spoj za uporabu prema zahtjevu 3 ili zahtjevu 4 gdje je područje medicine liječenje kronične upalne bolesti ili tumora koji eksprimira PPAR i EGF.
6. Spoj za uporabu prema zahtjevu 5 gdje se tumori izabiru iz grupe koja obuhvaća tumor jednjaka, želuca, gušterače, kolona, prostate, dojke, maternice i priraslica maternici, bubrega i pluća.
7. Spoj za uporabu prema zahtjevu 6 gdje je spoj (+-)-2-metoksi-3-(4’-aminofenil) propionska kiselina (spoj 34) ili (+-)-2-etoksi-3-(4’-aminofenil) propionska kiselina (spoj 39).
8. Spoj za uporabu prema zahtjevu 5 gdje je kronična upalna bolest Crohnova bolest ili ulcerozni rektokolitis.
9. Spoj za uporabu prema zahtjevu 8 gdje je spoj (+-)-2-metoksi-3-(4’-aminofenil) propionska kiselina (spoj 34) (+-)-2-etoksi-3-(4’-aminofenil) propionska kiselina (spoj 39) ili (+-)-2-etoksi-3-(3’-aminofenil) propionska kiselina (spoj 40)
10. Spoj za uporabu prema bilo kojem od zahtjeva 3 do 9 gdje se radi o uporabi spoja u mješavini u kojoj je jedan enantiomer u suvišku u odnosu na drugi, u bilo kojem omjeru.
11. Farmaceutska smjesa koja kao djelatnu tvar sadrži jedan ili više spojeva prema zahtjevima 1 do 3 u kombinaciji s jednim ili više farmaceutski prihvatljivih pomoćnih tvari ili adjuvansa.
HRP20130549TT 2005-07-22 2006-07-24 Spojevi i njihove soli specifični za ppar receptore i egf receptore te njihova primjena u području medicine HRP20130549T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000389A ITRM20050389A1 (it) 2005-07-22 2005-07-22 Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
EP06766085.2A EP1910270B3 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
PCT/IE2006/000078 WO2007010516A2 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field

Publications (2)

Publication Number Publication Date
HRP20130549T1 HRP20130549T1 (en) 2013-07-31
HRP20130549T4 true HRP20130549T4 (hr) 2016-07-15

Family

ID=37579831

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130549TT HRP20130549T4 (hr) 2005-07-22 2006-07-24 Spojevi i njihove soli specifični za ppar receptore i egf receptore te njihova primjena u području medicine

Country Status (23)

Country Link
US (6) US8153841B2 (hr)
EP (1) EP1910270B3 (hr)
JP (1) JP5312026B2 (hr)
KR (1) KR101317519B1 (hr)
CN (2) CN102020577B (hr)
AU (1) AU2006271165C1 (hr)
CA (1) CA2616146C (hr)
CY (1) CY1114294T1 (hr)
DK (1) DK1910270T6 (hr)
EA (2) EA014665B3 (hr)
ES (1) ES2421260T7 (hr)
HR (1) HRP20130549T4 (hr)
IL (2) IL188878A (hr)
IT (1) ITRM20050389A1 (hr)
MX (1) MX366596B (hr)
NO (1) NO340680B1 (hr)
NZ (2) NZ566045A (hr)
PL (1) PL1910270T6 (hr)
PT (1) PT1910270E (hr)
SI (1) SI1910270T1 (hr)
UA (1) UA100359C2 (hr)
WO (1) WO2007010516A2 (hr)
ZA (2) ZA200801671B (hr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
ITMI20072429A1 (it) * 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
UA107562C2 (uk) * 2008-12-05 2015-01-26 Спосіб лікування псоріазу
AU2010213093B2 (en) * 2009-02-16 2016-01-07 Nogra Pharma Limited Alkylamido compounds and uses thereof
US9096531B2 (en) 2010-05-24 2015-08-04 Toa Eiyo Ltd. Fused imidazole derivative
CN109999017A (zh) 2012-02-09 2019-07-12 诺格拉制药有限公司 治疗纤维化的方法
NZ631049A (en) * 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
FR2996545B1 (fr) 2012-10-08 2016-03-25 Ecole Polytech Procede microfluidique de traitement et d'analyse d'une solution contenant un materiel biologique, et circuit microfluidique correspondant.
US10257875B2 (en) * 2014-03-20 2019-04-09 Kyocera Corporation User terminal, communication control method, and base station
WO2017093444A1 (en) * 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
US20220000818A1 (en) 2019-01-25 2022-01-06 Nogra Pharma Limited Compositions for use in preventing acne
SMT202500054T1 (it) 2019-02-08 2025-03-12 Nogra Pharma Ltd Processo per produrre acido 3-(4'-amminofenil)-2-metossipropionico, e relativi analoghi e intermedi
WO2025132838A1 (en) 2023-12-20 2025-06-26 Nogra Pharma Limited Acne topical formulations

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) * 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) * 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
DE3164618D1 (en) 1980-12-22 1984-08-09 Schering Ag 3-substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
DE3786452T2 (de) * 1987-02-05 1993-10-21 Kureha Chemical Ind Co Ltd Benzylether-Verbindungen und Verfahren zu ihrer Herstellung.
NZ224087A (en) 1987-04-01 1990-08-28 Dak Lab As Topical pharmaceutical compositions containing 4- or 5- amino salicylic acid or a functional derivative thereof
DE68919009T2 (de) 1988-05-05 1995-02-23 Tillotts Pharma Ag Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
ATE256468T1 (de) 1990-10-22 2004-01-15 Gastro Services Pty Ltd Behandlung von nicht-entzündlichen darmerkrankungen
US5262549A (en) 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
CA2120367C (en) 1992-06-30 2004-05-11 Howard K. Shapiro Compositions and use of pharmaceutical compositions in the treatment of symptoms of disorders related to chronic inflammatory diseases and etiologically related symptomology
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
CA2190107A1 (en) 1994-05-11 1995-11-23 Howard K. Shapiro Compositions for treatment of chronic inflammatory diseases
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
CA2215160A1 (en) 1995-03-28 1996-10-03 Maria-Helena Joris Jozef Verlinden Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
WO1999015520A1 (fr) * 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Composes de benzene fusionnes ou non fusionnes
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
US20040034067A1 (en) 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
DE60013491T2 (de) 2000-04-19 2005-09-01 Neurotech Co., Ltd., Suwon Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems
ES2312432T3 (es) * 2000-05-29 2009-03-01 Kyorin Pharmaceutical Co., Ltd. Derivados del acido fenilpropionico sustituidos.
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
AU8531101A (en) 2000-08-29 2002-03-13 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
JPWO2002046161A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
WO2002085123A1 (en) 2001-04-18 2002-10-31 Merck & Co., Inc. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
IL161429A0 (en) * 2001-10-16 2004-09-27 Reddys Lab Ltd Dr Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing the same
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
CA2527861A1 (en) 2003-07-21 2005-02-10 Applied Research Systems Ars Holding N.V. Alkynyl aryl carboxamides
WO2005039590A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
EP1680397A2 (en) * 2003-10-28 2006-07-19 Dr. Reddy's Laboratories Ltd. Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
JP2007513173A (ja) 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US20090054312A1 (en) 2007-08-22 2009-02-26 Wolf Dieter A SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
AU2010213093B2 (en) 2009-02-16 2016-01-07 Nogra Pharma Limited Alkylamido compounds and uses thereof
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2013012662A2 (en) 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
ES2602075T3 (es) 2011-10-31 2017-02-17 Larsen, Claus Selch Profármacos de agentes antiinflamatorios no esteroideos (AINE)
CN109999017A (zh) 2012-02-09 2019-07-12 诺格拉制药有限公司 治疗纤维化的方法
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CN104619687A (zh) 2012-06-01 2015-05-13 诺格拉制药有限公司 能够调节t-细胞应答的双环杂环及其使用方法
PL2895160T3 (pl) 2012-09-13 2018-09-28 Nogra Pharma Limited Sposoby leczenia stanów związanych z włosami
CN104736149A (zh) 2012-09-13 2015-06-24 诺格拉制药有限公司 抑制毛发生长的方法
US20180193361A1 (en) 2015-04-02 2018-07-12 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
HK1252978A1 (zh) 2015-06-15 2019-06-06 Nmd Pharma Aps 用於治療神經肌肉病癥的化合物

Also Published As

Publication number Publication date
EP1910270A2 (en) 2008-04-16
ES2421260T7 (es) 2016-10-11
US20150265562A1 (en) 2015-09-24
CN102020577B (zh) 2013-03-13
US9561202B2 (en) 2017-02-07
KR101317519B1 (ko) 2013-10-15
PL1910270T3 (pl) 2013-09-30
DK1910270T6 (en) 2016-08-29
CY1114294T1 (el) 2016-08-31
ES2421260T3 (es) 2013-08-30
US8153841B2 (en) 2012-04-10
AU2006271165B2 (en) 2012-01-19
ZA201008268B (en) 2012-04-25
EP1910270B1 (en) 2013-05-08
CN101243039B (zh) 2013-04-03
AU2006271165A1 (en) 2007-01-25
EA201000708A1 (ru) 2010-10-29
EA014665B3 (ru) 2016-09-30
EA014665B1 (ru) 2010-12-30
BRPI0613396A2 (pt) 2011-01-11
KR20080039428A (ko) 2008-05-07
US8710100B2 (en) 2014-04-29
EA200800372A1 (ru) 2008-06-30
UA100359C2 (uk) 2012-12-25
PL1910270T6 (pl) 2017-05-31
US20130005813A1 (en) 2013-01-03
BRPI0613396A8 (pt) 2017-12-26
US20150045436A1 (en) 2015-02-12
SI1910270T1 (sl) 2013-08-30
NO340680B1 (no) 2017-05-29
ZA200801671B (en) 2011-02-23
HRP20130549T1 (en) 2013-07-31
US10016381B2 (en) 2018-07-10
MX366596B (es) 2019-07-15
JP2009502777A (ja) 2009-01-29
DK1910270T3 (da) 2013-07-01
AU2006271165C1 (en) 2016-11-17
CN102020577A (zh) 2011-04-20
CN101243039A (zh) 2008-08-13
JP5312026B2 (ja) 2013-10-09
CA2616146C (en) 2015-06-30
EA017566B1 (ru) 2013-01-30
CA2616146A1 (en) 2007-01-25
NO20080325L (no) 2008-04-16
PT1910270E (pt) 2013-07-17
IL188878A (en) 2013-04-30
EP1910270B3 (en) 2016-05-11
US9345680B2 (en) 2016-05-24
ITRM20050389A1 (it) 2007-01-23
US20170312239A1 (en) 2017-11-02
NZ592228A (en) 2012-10-26
US9133099B2 (en) 2015-09-15
US20150265563A1 (en) 2015-09-24
WO2007010516A2 (en) 2007-01-25
IL205992A (en) 2014-05-28
WO2007010516A3 (en) 2007-03-29
US20090048343A1 (en) 2009-02-19
IL188878A0 (en) 2008-04-13
NZ566045A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
HRP20130549T4 (hr) Spojevi i njihove soli specifični za ppar receptore i egf receptore te njihova primjena u području medicine
HRP20160014T1 (hr) Derivati 1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamida kao inhibitori fosfatidilinozitol 3-kinaze (pi3k), koji su korisni u lijeäśenju proliferativnih bolesti
ES2240992T3 (es) Uso de un r-nsaid en una composicion protectora para el tratamiento del cancer colorrectal.
JP2009502777A5 (hr)
HRP20170791T1 (hr) Smjesa rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil]-fosfata
ES2491226T3 (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriaris
JP2015511609A5 (hr)
JP2010519260A5 (hr)
WO2010062688A3 (en) Dosage form for insertion into the mouth
HRP20171755T1 (hr) Postupak kristalizacije i biološka raspoloživost
BRPI0818006B8 (pt) compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
RU2015121367A (ru) Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
JP2012502015A5 (hr)
RU2007145489A (ru) Фармацевтические композиции и способы лечения рака и его метастазов
JP2013501224A5 (hr)
HRP20211652T1 (hr) Pirimidopirimidinoni korisni kao inhibitor wee-1 kinaze
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
RU2014141934A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями
JP2017519028A5 (hr)
JP2021105005A5 (hr)
JP2013544892A5 (hr)
JP2013508384A5 (hr)
JP2010500284A5 (hr)
HRP20171783T1 (hr) Derivati imidazopirazinona
CN204890930U (zh) 一种消化内科食道涂药器